Non-compliant and compliant balloons for endovascular rescue therapy of cerebral vasospasm after spontaneous subarachnoid haemorrhage: experiences of a single- centre institution with radiological follow- up of the treated vessel segments
作者机构:NeuroradiologyUniversity Medical Center Schleswig Holstein Lubeck CampusLubeckGermany NeurosurgeryUniversity Medical Center Schleswig Holstein Lubeck CampusLubeckGermany
出 版 物:《Stroke & Vascular Neurology》 (卒中与血管神经病学(英文))
年 卷 期:2021年第6卷第1期
页 面:16-24页
核心收录:
学科分类:1002[医学-临床医学] 100204[医学-神经病学] 10[医学]
摘 要:Background For endovascular rescue therapy(ERT)of cerebral vasospasm(CVS)due to spontaneous subarachnoid haemorrhage(sSAH),non-compliant(NCB)and compliant(CB)balloons are used with both balloon types bearing the risk of vessel injury due to specific mechanical *** severe delayed arterial narrowing after transluminal balloon angioplasty(TBA)for CVS has sporadically been described,valid data concerning incidence and relevance are *** aim was to analyse the radiological follow-up(RFU)of differently TBA-treated arteries(CB or NCB).Methods Twelve patients with utilisation of either NCB or CB for CVS were retrospectively analysed for clinical characteristics,ERT,functional outcome after 3 months and *** with the initial angiogram,we classified delayed arterial narrowing as mild,moderate and severe(60% calibre reduction).Results Twenty-three arteries were treated with CB,seven with *** median first RFU was 11 months after TBA with CB and 10 after *** was performed with catheter angiography in 18 arteries(78%)treated with CB and in five(71%)after NCB;magnetic resonance angiography was acquired in five vessels(22%)treated with CB and in two(29%)after *** arterial narrowing was detected in three arteries(13%)after CB and in one(14%)after *** or severe findings were neither detected after use of CB nor *** We found no relevant delayed arterial narrowing after TBA for CVS after *** previous assumptions that CB provides for more dilatation in segments adjacent to CVS,we observed no disadvantages concerning long-term adverse *** data support TBA as a low-risk treatment option.